Your Compliance Extends Beyond Your Walls A pharmaceutical manufacturer’s regulatory responsibility does not end at the boundary of its own facility. Under Good Manufacturing Practice regulations across all major jurisdictions, the organisation that holds the manufacturing authorisation …

The Technology Gap in GMP Audit Programmes Pharmaceutical quality assurance has always been a documentation-intensive discipline, but the tools with which that documentation is managed have evolved unevenly across the industry. In manufacturing and laboratory operations, technology adoption ha…

What Audit Findings Tell You About Your Organisation Audit findings are more than a compliance report card. They are a diagnostic signal, revealing where an organisation’s quality management system is under stress, where process discipline is inconsistent, and where regulatory risk is ac…

The Compliance Challenge Is Not Proportional to Size Regulatory expectations for Good Manufacturing Practice do not scale with the size of a pharmaceutical company. A small manufacturer or contract development organisation operating under MHRA, FDA, or EMA oversight faces essentially the same …

Why Risk Is the Right Framework for GMP Auditing Most pharmaceutical and life sciences organisations treat GMP audits as compliance exercises: a scheduled review, a checklist, a report. That approach is not wrong, but it is increasingly insufficient. Regulatory bodies have moved well beyond th…